Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
1 other identifier
observational
70
1 country
1
Brief Summary
in this resarch we will use ELISA Technique to estimate Human Transcriptional Activator(MYB) Expression .compare it by Immmunohistochemistry analysis of MYB Expression in the malignant and benign salivary gland tumor
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 26, 2018
CompletedFirst Posted
Study publicly available on registry
September 27, 2018
CompletedStudy Start
First participant enrolled
January 12, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2021
CompletedJuly 21, 2020
July 1, 2020
2.6 years
September 26, 2018
July 19, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas
Diagnostic Accuracy of Human Transcriptional Activator(MYB) Expression by ELISA Technique Versus Immmunohistochemistry in Detecting Salivary Gland Carcinomas.
two years
Study Arms (2)
Group I
patients suffering from malignant salivary gland tumors.
Group II
patients suffering from benign salivary gland tumors.
Interventions
ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Eligibility Criteria
Egyptian population
You may qualify if:
- Patients with clinically evident salivary gland tumors; malignant tumors will be recruited in group I
- Benign tumors will be recruited in group II.
You may not qualify if:
- Subjects taking any drugs inducing any changes that could affect the salivary glands.
- Pregnant females.
- Subjects having any allergies, infectious or autoimmune diseases.
- Subjects having any metabolic disorders that can be manifested with salivary gland swelling as diabetes mellitus.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
National Cancer Institute
Cairo, 11796, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- pricipal investegator
Study Record Dates
First Submitted
September 26, 2018
First Posted
September 27, 2018
Study Start
January 12, 2019
Primary Completion
September 1, 2021
Study Completion
December 1, 2021
Last Updated
July 21, 2020
Record last verified: 2020-07
Data Sharing
- IPD Sharing
- Will not share